<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acetohydroxamic acid: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acetohydroxamic acid: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Acetohydroxamic acid: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9210" href="/d/html/9210.html" rel="external">see "Acetohydroxamic acid: Drug information"</a> and <a class="drug drug_patient" data-topicid="10989" href="/d/html/10989.html" rel="external">see "Acetohydroxamic acid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F129938"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lithostat</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F996144"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Urinary Tract Product</span></li></ul></div>
<div class="block dop drugH1Div" id="F129947"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b098aa2-1067-4267-9fb1-e69f301c1da7">Chronic urea-splitting urinary infection; adjunct therapy to decrease urinary ammonia levels and alkalinity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic urea-splitting urinary infection; adjunct therapy to decrease urinary ammonia levels and alkalinity:</b> Children and Adolescents: Oral: Initial: 10 mg/kg/day in 2 or 3 divided doses; adjust dose as needed (higher or lower) for optimum therapeutic effect and minimization of side effects; in adults, usual dose is 250 mg/dose (10 to 15 mg/kg/day) and the maximum daily dose: 1,500 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Children and Adolescents: Reticulocyte count &gt;6%: Consider a reduction in the dosage.</p></div>
<div class="block dorp drugH1Div" id="F51154203"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, dosing adjustment suggested and for sCr &gt;2.5 mg/dL (or CrCl &lt;20 mL/minute), use is contraindicated.</p></div>
<div class="block dohp drugH1Div" id="F51154204"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F129940"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9210" href="/d/html/9210.html" rel="external">see "Acetohydroxamic acid: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c07aba5c-95b7-4d22-983a-e063ce89fdb4">Chronic urea-splitting urinary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic urea-splitting urinary infection:</b>
<b>Oral:</b> Initial: 12 mg/kg/day in 3 to 4 divided doses. Maintenance: 250 mg 3 to 4 times daily for a total daily dose of 10 to 15 mg/kg/day. Maximum daily dose: 1,500 mg/day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990183"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Serum creatinine &gt;1.8 mg/dL: 10 to 15 mg/kg/day divided every 12 hours; maximum daily dose: 1,000 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum creatinine &gt;2.5 mg/dL (or CrCl &lt;20 mL/minute): Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50987553"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F2613478"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (30%), malaise (20% to 25%), anxiety (20%), depression (20%), nervousness (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (20% to 25%), nausea (20% to 25%), vomiting (20% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (3% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis (rare), embolism, flushing, palpitations, phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, macular eruption </p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Reticulocytosis (5% to 6%)</p></div>
<div class="block coi drugH1Div" id="F2523572"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Patients whose physical state and disease are amenable to definitive surgery and appropriate antimicrobial agents; patients whose urine is infected by non-urease-producing organisms; patients whose urinary infections can be controlled by culture-specific oral antimicrobial agents; patients whose renal function is poor (ie, serum creatinine &gt;2.5 mg/dL and/or creatinine clearance &lt;20 mL/minute); female patients who do not evidence a satisfactory method of contraception; pregnancy</p></div>
<div class="block war drugH1Div" id="F2613475"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: May suppress bone marrow function; use with caution in patients with prior bone marrow depression. Close monitoring of hematologic function is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Has been associated with hemolytic anemia (Coombs' negative), which may be associated with gastrointestinal distress (eg, nausea, vomiting, anorexia) and generalized malaise; use with caution in patients with anemia. In patients receiving therapy for &gt;2 weeks, monitor hematologic parameters (eg, CBC with reticulocytes) at 3-month intervals for the duration of treatment. If the reticulocyte count exceeds 6%, consider a reduction in the dosage. Anemia is usually reversible after treatment is discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: May cause hepatic injury; close monitoring of hepatic function is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rash: A nonpruritic, macular skin rash has occurred in the upper extremities and on the face of patients on long-term therapy, usually with concomitant ethanol use. The rash most often occurs 30 to 45 minutes after ethanol consumption and resolves spontaneously in 30 to 60 minutes. Patients should limit or avoid alcohol during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; close monitoring of renal function is recommended. Dosage adjustments recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Struvite kidney stones: Struvite stones, which occur as a result of urinary tract infections with urea splitting organisms, are typically surgically removed. However, in patients who are not candidates for surgical removal or in patients at risk for recurrent urinary tract infection with urease-producing organisms, treatment with acetohydroxamic acid may be beneficial (AUA guidelines [Pearle 2014]). Acetohydroxamic acid is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with acetohydroxamic acid may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with acetohydroxamic acid does not go beyond 7 years.</p></div>
<div class="block foc drugH1Div" id="F129930"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lithostat: 250 mg</p></div>
<div class="block geq drugH1Div" id="F129922"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F129933"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lithostat Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $7.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612178"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach, 1 hour before or 2 hours after meals. Administer 1 hour before or 2 hours after taking iron or any product that contains iron.</p></div>
<div class="block adm drugH1Div" id="F2613487"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach, 1 hour before or 2 hours after meals. Administer 1 hour before or 2 hours after taking iron or any product that contains iron.</p></div>
<div class="block sts drugH1Div" id="F15160703"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 15°C and 30°C (59°F and 86°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53565203"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunctive therapy in chronic urea-splitting urinary infection (FDA approved in children and adults)</p></div>
<div class="block mst drugH1Div" id="F129952"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lithostat may be confused with Lithobid</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298675"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2613482"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Acetohydroxamic Acid. Specifically, Alcohol (Ethyl) may increase the risk of Acetohydroxamic Acid associated rash.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F129937"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may decrease absorption of acetohydroxamic acid. Management: Administer on an empty stomach, 1 hour before or 2 hours after meals.</p></div>
<div class="block dic drugH1Div" id="F129934"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken on an empty stomach, 1 hour before or 2 hours after meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49088706"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in females of childbearing potential who are not using a reliable form of contraception.</p></div>
<div class="block pri drugH1Div" id="F13332940"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse effects were observed in animal reproduction studies. Use is contraindicated in pregnant women.</p></div>
<div class="block pha drugH1Div" id="F2613484"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acetohydroxamic acid inhibits bacterial urease enzymes, decreasing the formation of ammonia in the urine by urea-splitting organisms. A reduction in urinary ammonia and decreased pH may increase the activity of some antimicrobial agents. </p></div>
<div class="block phk drugH1Div" id="F15160704"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5 to 10 hours (increased in patients with reduced renal function).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 0.25 to 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (36% to 65% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F129935"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lithostat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Lithostat (acetohydroxamic acid) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24857648">
<a name="24857648"></a>Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. <i>J Urol</i>. 2014;192(2):316-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetohydroxamic-acid-pediatric-drug-information/abstract-text/24857648/pubmed" id="24857648" target="_blank">24857648</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117808 Version 34.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
